MtbΔfbpA
We have developed three live vaccine candidates by knocking out or deleting genes in Mycobacterium tuberculosis H37Rv. We named them as double knockout (DKO), Triple knockout (TKO), and quadruple knockout (QKO). These strains have the following gene deletions: DKO (Mtb∆fbpA-∆sapM), TKO (Mtb∆fbpA-∆sapM-∆zmp1), and (Mtb∆fbpA-∆sapM-∆zmp-∆dosR).
Read MoreSeV986A
Our group utilizes an replication-defective Sendai virus (SeV) as TB vaccine vector, and constructed SeV85AB and SeV986A vaccine. SeV986A expressed a fusion of acute- and latency-stage Mtb antigens (4 antigens). In murine models, it serves as a potent BCG-booster, significantly reducing bacterial burden in both active and latent infection challenges.
Read MorerBCG-LTAK63
rBCG-LTAK63 is an unmarked recombinant BCG strain expressing the subunit A of detoxified E. coli Heat-Labile Toxin (LTAK63) as adjuvant. rBCG-LTAK63 induced protection superior to standard BCG, through enhanced and regulated Th1/Th17 responses, and both early effector and long-term TRM cell responses with reduced lung inflammation and improved immunopathological control.
Read MoreChAdOx1.5Ag/MVA.5Ag
ChAdOx1.5Ag is a recombinant, replication deficient chimpanzee adenovirus, expressing the four antigens of the mycobacterium Esx-5a system (PPE15, PE8, EsxI, EsxJ), along with Ag85A. In mice, ChAdOx1.5Ag improved the efficacy of BCG in the lung and spleen, and a further boost with MVA.5Ag further improved efficacy in the spleen. ChAdOx1.5Ag/MVA.5Ag was also promising in non-human…
Read MoreSpore-FP1
Spore-FP1 is a subunit vaccine candidate consisting of inactivated Bacillus subtilis spores coated with the FP1 fusion protein and formulated with Poly(I:C) adjuvant. FP1 fusion protein comprises Ag85B, Acr/HspX and the N-terminal domain of HBHA antigen. It is intended as a mucosal boost vaccine in BCG-immunised hosts.
Read More